Asia-Pacific Fertility Services Market Expected to Reach $20,492.95 Million by 2030

According to a new report published by Allied Market Research, titled, “Asia-Pacific Fertility Services Market by Procedure, Service, End User, and Country: Opportunity Analysis and Industry Forecast, 2021–2030," The Asia-Pacific fertility services market was valued at $4,529.06 million in 2020, and is expected to reach $20,492.95 million by 2030, registering a CAGR of 15.5% from 2021 to 2030.

Fertility services include different procedures used to treat fertility and genetic issues and assist with conception. There are different fertility services known as assisted reproductive technology (ART) methods, helping single parents and couples around the world in bearing a child. The surge in prevalence of delayed pregnancies opted by women and growth in infertility rates across the world drive the growth of the Asia-Pacific fertility services industry.

The pandemic affected the Asia-Pacific fertility services market negatively. Many fertility clinics across the region stopped taking in new patients who needed fertility treatment in the initial phase of the pandemic-induced lockdowns. Some women even postponed their fertility consultations with gynecologists. However, the trends for different Asian countries seemed to be different. For instance, in Thailand some cities like Phuket were on full lockdown, however, the fertility clinics in Bangkok remained open. In addition, private fertility clinics operated normally in Singapore.

The availability of the latest IVF devices throughout the region is also anticipated to fuel market growth. Novel fertility procedures are also known to have a better success rate and higher chances of fertilization in minimum attempts. Additional equipment and devices are now being used to monitor the development of the zygote during the process. This includes imaging systems, incubators, and monitoring software.

Market players are even developing advanced techniques that help maintain required hormone levels in the mother. For instance, Merck KGaA received approval for its pergoveris pen. This product is a luteinizing hormone (LH) and follicular stimulating hormone (FSH) combination that can be readily used in liquid form.

The main factors that drive the growth of the Asia-Pacific fertility services market include the rise in delayed pregnancies in women, rising awareness regarding different fertility procedures, and a higher acceptance rate for novel techniques such as hormone therapies and egg freezing banks in the region. Furthermore, women in the region are also at risk of developing gynecological conditions that hinder them from conceiving. These conditions are aggravated by a sedentary and fast-paced lifestyle and include polycystic ovarian syndrome, fibroids, and endometriosis. Hence, these factors are also anticipated to fuel market growth.

By procedure, the IVF with ICSI (intracytoplasmic sperm injection) segment accounted for a large market share. This segment is expected to exhibit a prominent growth rate, owing to some key factors such as higher success rates associated with ICSI-IVF in case of poor sperm morphology, poor sperm motility, low sperm count, and others.

By service, the fresh non-donor segment accounted for a major share of the market in 2020. This segment is expected to exhibit a prominent growth rate, owing to a rapid increase in infertility rate, technological advancements, and change in lifestyle.

By end user, the fertility clinics segment held a substantial revenue Asia-Pacific fertility services market share in 2020. This segment is expected to exhibit a considerable growth rate, owing to delayed pregnancy trends in women, advantages of fresh embryo transfer over the frozen embryo technique, increase in the rate of infertility, and higher success rate of this technique.

By country, China holds a significant market share due to the lesser cost of fertility services and better policies and legal environment for procedures such as surrogacy. In addition, countries such as China and Thailand are also experiencing higher medical tourism for fertility services for offering them at a much lower price than the countries in other regions.

Key Findings Of The Study

• By procedure type, the IVF with ICSI segment is expected to register the fastest CAGR during the forecast period
• By service, the fresh non-donor segment dominated the Asia-Pacific fertility services market in 2020
• By end user, the fertility clinics segment spearheaded the market in 2020 and is expected to remain dominant throughout the forecast period
• By country, China is expected to experience Asia-Pacific fertility services market growth at the highest rate during the forecast period.